Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: clinical and genetic features of two cases
- 30 June 2003
- journal article
- case report
- Published by Elsevier BV in Cancer Genetics and Cytogenetics
- Vol. 143 (2), 178-181
- https://doi.org/10.1016/s0165-4608(02)00859-2
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- P53 and PML: new partners in tumor suppressionTrends in Cell Biology, 2001
- Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor PrognosisJournal of Clinical Oncology, 2001
- Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemiaBritish Journal of Haematology, 2001
- Emergence of secondary acute leukemia in a patient treated for osteosarcoma: implications of germline TP53 mutationsMedical and Pediatric Oncology, 1998
- Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patientsCancer Genetics and Cytogenetics, 1997
- Alterations of p53 and Rb genes in a novel human GM‐CSF‐dependent myeloid cell line (OHN‐GM) established from therapy‐related leukaemiaBritish Journal of Haematology, 1997
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997
- Diagnosis of acute promyelocytic leukaemia by RT‐PCR: detection of PML‐RARA and RARA‐PML fusion transcriptsBritish Journal of Haematology, 1992